Phase I trial of combinations of recombinant interferons β(ser) and γ in patients with advanced malignancy

J. H. Schiller, B. Storer, J. K V Willson, E. C. Borden

Research output: Chapter in Book/Report/Conference proceedingChapter

15 Citations (Scopus)

Abstract

Based upon in vitro and in vivo synergistic activity of Type I and Type II interferons (IFNs) in preclinical in vitro and in vivo studies, we initiated a phase I trial evaluating the doses, safety, and pharmacokinetics of combinations of recombinant DNA-produced human IFN-β(ser) and IFN-γ in 27 patients with cancer. Twenty-four patients were treated with a 2-hour infusion of IFN-γ, followed by a 10-minute iv injection of IFN-β(ser), three times a week. Patients were entered on fixed dose levels of 1 x 106, 3 x 106, 10 x 106, 30 x 106, and 100 x 106 units of each IFN. In addition, three patients were treated at the highest dose level with a 10-minute iv infusion of IFN-γ and a 10-minute iv infusion of IFN-β(ser). The maximally tolerated dose when administered by this schedule for ≥ 4 weeks was 30 x 106 units of each IFN. Dose-limiting side effects at doses of 100 x 106 units of each IFN consisted of fatigue, nausea, vomiting, anorexia, paralytic ileus, and neutropenia. The most common side effects at the three highest dose levels were fever, rigors often requiring parenteral meperidine, and constitutional symptoms. Reversible elevations in SGOT and LDH were also noted. Serum IFN levels were dose related, with peak titers occurring immediately after IFN administration. One patient with a nodular mixed lymphoma had a partial response which has been sustained for over 1 year. We conclude that combinations of IFN-β(ser) and IFN-γ can be safely administered on a chronic basis without enhanced or cumulative toxic effects.

Original languageEnglish (US)
Title of host publicationCancer Treatment Reports
Pages945-952
Number of pages8
Volume71
Edition10
StatePublished - 1987

Fingerprint

Interferons
Neoplasms
Intestinal Pseudo-Obstruction
Meperidine
Follicular Lymphoma
Maximum Tolerated Dose
Recombinant DNA
Poisons
Anorexia
Aspartate Aminotransferases
Neutropenia
Non-Hodgkin's Lymphoma
Nausea
Interferon-gamma
Vomiting
Fatigue
Appointments and Schedules
Fever
Pharmacokinetics
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schiller, J. H., Storer, B., Willson, J. K. V., & Borden, E. C. (1987). Phase I trial of combinations of recombinant interferons β(ser) and γ in patients with advanced malignancy. In Cancer Treatment Reports (10 ed., Vol. 71, pp. 945-952)

Phase I trial of combinations of recombinant interferons β(ser) and γ in patients with advanced malignancy. / Schiller, J. H.; Storer, B.; Willson, J. K V; Borden, E. C.

Cancer Treatment Reports. Vol. 71 10. ed. 1987. p. 945-952.

Research output: Chapter in Book/Report/Conference proceedingChapter

Schiller, JH, Storer, B, Willson, JKV & Borden, EC 1987, Phase I trial of combinations of recombinant interferons β(ser) and γ in patients with advanced malignancy. in Cancer Treatment Reports. 10 edn, vol. 71, pp. 945-952.
Schiller JH, Storer B, Willson JKV, Borden EC. Phase I trial of combinations of recombinant interferons β(ser) and γ in patients with advanced malignancy. In Cancer Treatment Reports. 10 ed. Vol. 71. 1987. p. 945-952
Schiller, J. H. ; Storer, B. ; Willson, J. K V ; Borden, E. C. / Phase I trial of combinations of recombinant interferons β(ser) and γ in patients with advanced malignancy. Cancer Treatment Reports. Vol. 71 10. ed. 1987. pp. 945-952
@inbook{b7dfc7cc40204ef3b9616bc393d05a73,
title = "Phase I trial of combinations of recombinant interferons β(ser) and γ in patients with advanced malignancy",
abstract = "Based upon in vitro and in vivo synergistic activity of Type I and Type II interferons (IFNs) in preclinical in vitro and in vivo studies, we initiated a phase I trial evaluating the doses, safety, and pharmacokinetics of combinations of recombinant DNA-produced human IFN-β(ser) and IFN-γ in 27 patients with cancer. Twenty-four patients were treated with a 2-hour infusion of IFN-γ, followed by a 10-minute iv injection of IFN-β(ser), three times a week. Patients were entered on fixed dose levels of 1 x 106, 3 x 106, 10 x 106, 30 x 106, and 100 x 106 units of each IFN. In addition, three patients were treated at the highest dose level with a 10-minute iv infusion of IFN-γ and a 10-minute iv infusion of IFN-β(ser). The maximally tolerated dose when administered by this schedule for ≥ 4 weeks was 30 x 106 units of each IFN. Dose-limiting side effects at doses of 100 x 106 units of each IFN consisted of fatigue, nausea, vomiting, anorexia, paralytic ileus, and neutropenia. The most common side effects at the three highest dose levels were fever, rigors often requiring parenteral meperidine, and constitutional symptoms. Reversible elevations in SGOT and LDH were also noted. Serum IFN levels were dose related, with peak titers occurring immediately after IFN administration. One patient with a nodular mixed lymphoma had a partial response which has been sustained for over 1 year. We conclude that combinations of IFN-β(ser) and IFN-γ can be safely administered on a chronic basis without enhanced or cumulative toxic effects.",
author = "Schiller, {J. H.} and B. Storer and Willson, {J. K V} and Borden, {E. C.}",
year = "1987",
language = "English (US)",
volume = "71",
pages = "945--952",
booktitle = "Cancer Treatment Reports",
edition = "10",

}

TY - CHAP

T1 - Phase I trial of combinations of recombinant interferons β(ser) and γ in patients with advanced malignancy

AU - Schiller, J. H.

AU - Storer, B.

AU - Willson, J. K V

AU - Borden, E. C.

PY - 1987

Y1 - 1987

N2 - Based upon in vitro and in vivo synergistic activity of Type I and Type II interferons (IFNs) in preclinical in vitro and in vivo studies, we initiated a phase I trial evaluating the doses, safety, and pharmacokinetics of combinations of recombinant DNA-produced human IFN-β(ser) and IFN-γ in 27 patients with cancer. Twenty-four patients were treated with a 2-hour infusion of IFN-γ, followed by a 10-minute iv injection of IFN-β(ser), three times a week. Patients were entered on fixed dose levels of 1 x 106, 3 x 106, 10 x 106, 30 x 106, and 100 x 106 units of each IFN. In addition, three patients were treated at the highest dose level with a 10-minute iv infusion of IFN-γ and a 10-minute iv infusion of IFN-β(ser). The maximally tolerated dose when administered by this schedule for ≥ 4 weeks was 30 x 106 units of each IFN. Dose-limiting side effects at doses of 100 x 106 units of each IFN consisted of fatigue, nausea, vomiting, anorexia, paralytic ileus, and neutropenia. The most common side effects at the three highest dose levels were fever, rigors often requiring parenteral meperidine, and constitutional symptoms. Reversible elevations in SGOT and LDH were also noted. Serum IFN levels were dose related, with peak titers occurring immediately after IFN administration. One patient with a nodular mixed lymphoma had a partial response which has been sustained for over 1 year. We conclude that combinations of IFN-β(ser) and IFN-γ can be safely administered on a chronic basis without enhanced or cumulative toxic effects.

AB - Based upon in vitro and in vivo synergistic activity of Type I and Type II interferons (IFNs) in preclinical in vitro and in vivo studies, we initiated a phase I trial evaluating the doses, safety, and pharmacokinetics of combinations of recombinant DNA-produced human IFN-β(ser) and IFN-γ in 27 patients with cancer. Twenty-four patients were treated with a 2-hour infusion of IFN-γ, followed by a 10-minute iv injection of IFN-β(ser), three times a week. Patients were entered on fixed dose levels of 1 x 106, 3 x 106, 10 x 106, 30 x 106, and 100 x 106 units of each IFN. In addition, three patients were treated at the highest dose level with a 10-minute iv infusion of IFN-γ and a 10-minute iv infusion of IFN-β(ser). The maximally tolerated dose when administered by this schedule for ≥ 4 weeks was 30 x 106 units of each IFN. Dose-limiting side effects at doses of 100 x 106 units of each IFN consisted of fatigue, nausea, vomiting, anorexia, paralytic ileus, and neutropenia. The most common side effects at the three highest dose levels were fever, rigors often requiring parenteral meperidine, and constitutional symptoms. Reversible elevations in SGOT and LDH were also noted. Serum IFN levels were dose related, with peak titers occurring immediately after IFN administration. One patient with a nodular mixed lymphoma had a partial response which has been sustained for over 1 year. We conclude that combinations of IFN-β(ser) and IFN-γ can be safely administered on a chronic basis without enhanced or cumulative toxic effects.

UR - http://www.scopus.com/inward/record.url?scp=0023640676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023640676&partnerID=8YFLogxK

M3 - Chapter

C2 - 3115570

AN - SCOPUS:0023640676

VL - 71

SP - 945

EP - 952

BT - Cancer Treatment Reports

ER -